Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir and Ruzasvir in chronic hepatitis C
NCT05904470Phase 2Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of bemnifosbuvir in hepatitis C (HCV), sponsored by Atea Pharmaceuticals. Started May 2023; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05904470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904470.